Palvella Therapeutics Announces Landmark FY2025 Results and Corporate Update: Progress Toward First FDA Approval, Robust Cash Position, and Pipeline Expansion

Palvella Therapeutics, Inc. (Nasdaq: PVLA) has released its full year 2025 financial results and a comprehensive corporate update, underscoring significant clinical, operational, and financial milestones that are likely to be highly relevant for investors and may materially impact share value.

Key Highlights

• QTORIN™ Rapamycin NDA Submission on Track: Palvella plans to submit a New Drug Application (NDA) for QTORIN™ rapamycin for microcystic lymphatic malformations (microcystic LMs) in the second half of 2026. This therapy could become the first FDA-approved treatment for a rare, lifelong disease affecting over 30,000 diagnosed patients in the U.S.
• Positive Phase 3 SELVA Results for Microcystic LMs: February 2026 topline data met primary and secondary endpoints with high statistical significance. Notably, 95% of participants aged 6+ improved, and 86% were rated as “Much Improved” or “Very Much Improved” at 24 weeks. QTORIN™ rapamycin was well-tolerated, with no drug-related serious adverse events and consistently low systemic rapamycin levels.
• Phase 3 and Phase 2 Trials Planned Across Pipeline:
  • Phase 3 trial for QTORIN™ rapamycin in cutaneous venous malformations (VMs) to initiate in 2H 2026.
  • Phase 2 trial for QTORIN™ rapamycin in clinically significant angiokeratomas to start in Q2 2026 (earlier than previous guidance).
  • Phase 2 trial for QTORIN™ pitavastatin in disseminated superficial actinic porokeratosis (DSAP) planned for 2H 2026.
  • Plans to announce a fourth clinical indication for QTORIN™ rapamycin and a third QTORIN™ product candidate in 2H 2026, targeting additional rare diseases without FDA-approved therapies.
• Regulatory Momentum: QTORIN™ rapamycin holds Breakthrough Therapy, Fast Track, and Orphan designations. Pre-NDA meeting request submitted to FDA in March 2026, with the meeting anticipated in Q2 2026.
• Financial Strength:
  • Pro forma cash of approximately \$274 million at year-end 2025, reflecting net proceeds from an oversubscribed \$230 million equity financing completed in February 2026.
  • Cash and cash equivalents at December 31, 2025 were \$58.0 million.
  • Research and development expenses increased to \$22.8 million (from \$8.2 million in 2024), driven by clinical program expansion and increased headcount.
  • General and administrative expenses rose to \$15.8 million (from \$5.9 million in 2024), reflecting higher personnel costs and public company expenses.
  • Net loss attributable to common stockholders for 2025 was \$41.7 million, or \$3.71 per share, on 11.25 million weighted average shares outstanding.
• Leadership Expansion: Strategic hires include Jennifer McDonough (SVP, Market Access & Patient Services; previously with Krystal Biotech) and Sarah Foster (SVP, Human Resources; previously with Mineralys Therapeutics), bolstering launch-readiness and operational capacity.

Clinical Pipeline Developments

• Microcystic LMs: Positive SELVA Phase 3 trial results, strong efficacy and safety profile; NDA submission planned for 2H 2026, paving way for potential FDA approval in 1H 2027.
• Cutaneous Venous Malformations: Phase 2 TOIVA trial showed significant clinical improvements; plans to file for Breakthrough Therapy Designation in Q2 2026 and initiate pivotal Phase 3 trial in 2H 2026.
• Angiokeratomas: Fast Track Designation granted by FDA in December 2025; Phase 2 trial set for Q2 2026, targeting >50,000 diagnosed patients in the U.S. with no FDA-approved therapies.
• DSAP (Disseminated Superficial Actinic Porokeratosis): QTORIN™ pitavastatin introduced as a first pathogenesis-directed therapy; Phase 2 trial planned for 2H 2026.

Corporate and Financial Updates

• Public Offering: February 2026 saw an upsized and oversubscribed equity raise, bringing in \$230 million gross proceeds and substantially strengthening the balance sheet and runway for commercialization and pipeline expansion.
• Cash Position: Pro forma cash at year-end 2025 is \$274 million, providing robust financial flexibility for clinical and commercial execution.
• Operational Expenditures: Increased R&D and G&A spend are aligned with expanded clinical activities and public company requirements.
• Share Structure: As of March 25, 2026, total shares outstanding are 15,708,420, including pre-funded warrant conversions.

Potential Share Price Catalysts

• First Potential FDA Approval: QTORIN™ rapamycin is on track for NDA submission in 2H 2026 and possible FDA approval in 1H 2027, which would be a transformative event for Palvella and for patients with microcystic LMs.
• Pipeline Expansion: Multiple upcoming clinical trial initiations and new product candidate announcements in 2026, each targeting rare diseases with substantial unmet needs and commercial potential.
• Regulatory Designations: Breakthrough Therapy, Fast Track, and Orphan Drug status for QTORIN™ programs signal expedited review and market exclusivity benefits.
• Financial Strength: The successful and oversubscribed equity financing positions Palvella to accelerate commercialization and pipeline growth, reducing risk and increasing upside potential.

Conference Call Details

Palvella will host a live webcast and conference call at 8:30 a.m. ET to discuss these results and updates. Investors can access the webcast and replay on the company website.

About Palvella Therapeutics

Founded by rare disease biotech veterans, Palvella is a clinical-stage biopharma focused on novel therapies for serious, rare skin diseases and vascular malformations. The company’s patented QTORIN™ platform underpins a robust pipeline targeting multiple indications with no FDA-approved therapies.

Disclaimer

This article contains forward-looking statements based on management’s current expectations, which are subject to risks, uncertainties, and assumptions. Actual results may differ materially from those indicated. Investors should review Palvella’s filings with the SEC for a complete description of risk factors. This article does not constitute investment advice. QTORIN™ rapamycin and QTORIN™ pitavastatin are investigational and not FDA-approved.

View PALVELLA THERAPEUTICS, INC. Historical chart here